Ki-Young Lee
Ki-Young Lee PhD
Professor: Graduate Program, Research Area, Laboratory, E-mail, Tel
Graduate Program Infection & Immunity
Research Area Innate immunity / Cancer immunotherapy / Autophagy
Laboratory Molecular Immunology Lab Laboratory
Tel +82-31-299-6225
Education & Careers
  • 1993 Chungbuk National University, College of Natural Sciences, Bachelor of Science
    1995 Chungbuk National University Graduate School of Pharmacy, Master of Pharmacy (Major in Immunology)
    2002 Yonsei University College of Engineering, Department of Biotechnology, Ph.D. (Immunology Major)
    1994 - 1998 Mokam Biotechnology Research Institute, Researcher
    2002 - 2003 Mokam Biotechnology Research Institute, Senior Researcher
    2003 - 2005 Yale University, Section of Immunobiology, Post-doc.
    2005 - 2007 Ulsan University College of Medicine, full-time lecturer
    2007 - present Sungkyunkwan University School of Medicine, Department of Molecular and Cellular Biology, Professor
Research Interest
Our laboratory conducts basic and translational studies related to innate immunity and cancer immunotherapy.

We have made major contributions to our understanding of the crosstalk between innate immune signals and autophagy in cancer diseases.

Current studies focus on the molecular mechanism and pathogenesis of cancer diseases regulated by autophagy and innate cellular components, working toward the goal of identifying novel therapeutic targets and strategies for cancer immunotherapy.

Major Areas of Research

&9702 Crosstalk between innate immune signals and autophagy in cancer diseases
&9702 Basic properties of innate immune cells in tumor microenvironment (TME)
&9702 Functional roles of Toll-like receptors in tumor microenvironment (TME)
&9702 Development of Humanized PDX mice in cancers
Representative Research Achievements
  • 1. Kim MJ, Min Y, Im JS, Son J, Lee JS, Lee KY. p62 is Negatively Implicated in the TRAF6-BECN1 Signaling Axis for Autophagy Activation and Cancer Progression by Toll-Like Receptor 4 (TLR4). Cells 2020 May 69(5). pii: E1142.

    2. Choi B, Lee JS, Kim SJ, Hong D, Park JB, Lee KY. Anti-tumor effects of anti-PD-1 antibody, pembrolizumab, in humanized NSG PDX mice xenografted with dedifferentiated liposarcoma. Cancer Lett. 2020 May 28478:56-69.

    3. Kim MJ, Min Y, Shim JH, Chun E, Lee KY. CRBN Is a Negative Regulator of Bactericidal Activity and Autophagy Activation Through Inhibiting the Ubiquitination of ECSIT and BECN1. Front Immunol. 2019 Sep 1810:2203

    4. Kim MJ, Min Y, Kwon J, Son J, Im JS, Shin J, Lee KY. p62 Negatively Regulates TLR4 Signaling via Functional Regulation of the TRAF6-ECSIT Complex. Immune Netw. 2019 Jun 1219(3):e16

    5. Min Y, Kim MJ, Lee S, Chun E, Lee KY. Inhibition of TRAF6 ubiquitin-ligase activity by peroxiredoxin-1 leads to inhibition of NFKB activation and autophagy activation. Autophagy. 201814(8):1347-1358.

    6. Min Y, Lee S, Kim MJ, Chun E, Lee KY. Ubiquitin-Specific Protease 14 Negatively Regulates Toll-Like Receptor 4-Mediated Signaling and Autophagy Induction by Inhibiting Ubiquitination of TAK1-Binding Protein 2 and Beclin 1. Front Immunol. 2017 Dec 158:1827

    7. Min Y, Wi SM, Shin D, Chun E, Lee KY. Peroxiredoxin-6 Negatively Regulates Bactericidal Activity and NF-kB Activity by Interrupting TRAF6-ECSIT Complex. Front Cell Infect Microbiol. 2017 Mar 24 7:94: 1-13